Chesapeake Partners Management’s Theravance Biopharma TBPH Stock Holding History

Chesapeake Partners Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$7.84M	Sell	345,735 -85,699	-20%	-$1.85M	1.17%	26
2016 Q1	$8.11M	Hold	431,434	–	–	0.63%	40
2015 Q4	$7.07M	Buy	431,434 +2,400	+0.6%	+$38.1K	0.4%	70
2015 Q3	$4.71M	Buy	429,034 +32,100	+8%	+$409K	0.25%	86
2015 Q2	$5.17M	Buy	396,934 +67,100	+20%	+$1.04M	0.2%	100
2015 Q1	$5.72M	Buy	329,834 +33,600	+11%	+$616K	0.26%	80
2014 Q4	$4.42M	Hold	296,234	–	–	0.17%	92
2014 Q3	$6.83M	Sell	296,234 -505,461	-63%	-$14.7M	0.25%	84
2014 Q2	$25.6M	Buy	+801,695	New	+$24.1M	0.77%	49

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Chesapeake Partners Management's TBPH Position: Q2 2016 in Review

Chesapeake Partners Management reduced its Theravance Biopharma (TBPH) stake by 20% in Q2 2016, selling an estimated $1.85M and leaving 345,735 shares worth $7.84M. The position accounts for 1.17% of the portfolio, ranked #26.

Chesapeake Partners Management first reported a position in TBPH in Q2 2014 and has held it in 9 quarters since. The position peaked at $25.6M in Q2 2014. 98 funds tracked by Wall St. Rank hold TBPH as of Q2 2016.

Chesapeake Partners Management held 345,735 shares of Theravance Biopharma worth $7.84M as of Q2 2016.
Chesapeake Partners Management sold 85,699 Theravance Biopharma shares in Q2 2016, an estimated $1.85M.
Theravance Biopharma made up 1.17% of Chesapeake Partners Management's portfolio in Q2 2016, its #26 holding.
Chesapeake Partners Management first reported a position in Theravance Biopharma in Q2 2014 and has held it in 9 quarters since.
Chesapeake Partners Management's Theravance Biopharma position peaked at $25.6M in Q2 2014.
98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2016.

Based on Chesapeake Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.